Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Oruka Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Oruka Therapeutics, Inc.’s stock price such as:

• Oruka Therapeutics, Inc.’s current stock price and volume
• Why Oruka Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for ORKA from analysts
• ORKA’s stock price momentum as measured by its relative strength

About Oruka Therapeutics, Inc. (ORKA)

Before we jump into Oruka Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Want to learn more about Oruka Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Oruka Therapeutics, Inc..

Oruka Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Oruka Therapeutics, Inc.’s stock price was $96.510.

Oruka Therapeutics, Inc. is down 1.38% from its previous closing price of $97.860.

During the last market session, Oruka Therapeutics, Inc.’s stock traded between $92.720 and $99.000. Currently, there are approximately 55.17 million shares outstanding for Oruka Therapeutics, Inc..

Oruka Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Oruka Therapeutics, Inc. Stock Price History

Oruka Therapeutics, Inc.’s (ORKA) price is currently up 1.41% so far this month.

During the month of July, Oruka Therapeutics, Inc.’s stock price has reached a high of $99.000 and a low of $80.720.

Over the last year, Oruka Therapeutics, Inc. has hit prices as high as $99.000 and as low as $12.840. Year to date, Oruka Therapeutics, Inc.’s stock is up 218.41%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Oruka Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there was 1 analyst who downgraded Oruka Therapeutics, Inc.’s stock and 2 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Oruka Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Oruka Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Oruka Therapeutics, Inc. (ORKA) by visiting AAII Stock Evaluator.

Relative Price Strength of Oruka Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Oruka Therapeutics, Inc. has a weighted four-quarter relative price strength of 56.62%, which translates to a Momentum Score of 99 and is considered to be Very Strong.

Want to learn more about how Oruka Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Oruka Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Oruka Therapeutics, Inc.’s stock price is $96.510, which is down 1.38% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Oruka Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.